Ana Arance
A5009056091- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Computational Drug Discovery Methods
- Monoclonal and Polyclonal Antibodies Research
- Click Chemistry and Applications
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Pharmaceutical studies and practices
- Brain Metastases and Treatment
- Synthesis and biological activity
- Synthesis of Tetrazole Derivatives
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Ocular Oncology and Treatments
- Nonmelanoma Skin Cancer Studies
- Protein Degradation and Inhibitors
- RNA modifications and cancer
- Lymphoma Diagnosis and Treatment
- Ferroptosis and cancer prognosis
Hospital Clínic de Barcelona
2016-2025
Consorci Institut D'Investigacions Biomediques August Pi I Sunyer
2015-2025
Universitat de Barcelona
2015-2025
Carol Davila University of Medicine and Pharmacy
2025
Hospital Universitario Infanta Leonor
2025
Grupo Español de Tumores Neuroendocrinos
2024
Hospital Universitari de Vic
2024
Hospital General Universitario De Valencia
2023
Centro de Salud Casa del Barco
2023
Tianjin Hi-Tech Superconducting Electronic Technology (China)
2020
The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits programmed cell death 1 (PD-1) and has antitumor activity in melanoma.In this randomized, controlled, phase 3 study, we assigned 834 melanoma a 1:1:1 ratio to receive pembrolizumab (at dose of 10 mg per kilogram body weight) every 2 weeks or four doses kilogram) weeks. Primary end points were progression-free overall survival.The estimated 6-month...
Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients ipilimumab-refractory metastatic melanoma. The use nivolumab previously untreated advanced melanoma has not been tested controlled study.We randomly assigned 418 who had without BRAF mutation to receive (at dose mg per kilogram body weight every 2 weeks and dacarbazine-matched placebo weeks) or dacarbazine 1000 square meter body-surface area nivolumab-matched weeks)....
Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In United States, has also as adjuvant therapy melanoma on basis recurrence-free overall survival rates were higher than those with placebo in a phase 3 trial. We wanted to determine efficacy nivolumab versus patients resected this randomized, double-blind, trial, we randomly assigned 906 (≥15 years age) who undergoing complete resection stage IIIB, IIIC, or IV receive an...
Combined BRAF and MEK inhibition, as compared with inhibition alone, delays the emergence of resistance reduces toxic effects in patients who have melanoma V600E or V600K mutations.
Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, nivolumab, PD-1-blocking has been shown be safe have antitumor activity in patients with previously treated melanoma, but the safety untreated melanoma need investigation.In this phase 2-3, global, double-blind, randomized trial, we evaluated relatlimab nivolumab as fixed-dose compared...
Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall (OS) with combination dabrafenib trametinib versus monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy safety after ≥36-month follow-up for all living patients.This double-blind, phase 3 enrolled previously untreated patients unresectable stage IIIC or IV Patients were randomized receive (150 mg twice daily) plus (2 once...
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety solid tumors, but most patients exhibit partial or complete resistance to treatment for reasons that are unclear. In this study, we evaluated tumor specimens from 65 with melanoma, lung nonsquamous, squamous cell head and neck cancers who were treated approved PD1-targeting antibodies pembrolizumab nivolumab. Tumor RNA before anti-PD1 therapy was analyzed on nCounter system using PanCancer...
This analysis provides long-term follow-up in patients with BRAF wild-type advanced melanoma receiving first-line therapy based on anti-programmed cell death 1 receptor inhibitors.To compare the 3-year survival nivolumab vs that dacarbazine previously untreated melanoma.This of a randomized phase 3 trial analyzed overall data from randomized, controlled, double-blind CheckMate 066 clinical trial. For this ongoing, multicenter academic institution trial, were enrolled January 2013 through...
Programmed cell death protein 1 (PD-1) blocking monoclonal antibodies improve the overall survival of patients with advanced melanoma but optimal duration treatment has not been established.
The CheckMate 066 trial investigated nivolumab monotherapy as first-line treatment for patients with previously untreated BRAF wild-type advanced melanoma. Five-year results are presented herein.In this multicenter, double-blind, phase III study, 418 untreated, unresectable, stage III/IV, melanoma were randomly assigned 1:1 to receive 3 mg/kg every 2 weeks or dacarbazine 1,000 mg/m2 weeks. primary end point was overall survival (OS), and secondary points included progression-free (PFS),...